{
    "nctId": "NCT00118053",
    "briefTitle": "Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer",
    "officialTitle": "A Phase II Trial of Taxotere, Carboplatin and Herceptin in Locally Advanced or Inflammatory Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 5,
    "primaryOutcomeMeasure": "Antitumor Activity as Measured by Response Rate",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer, meeting 1 of the following stage criteria:\n\n  * Stage IIB (T3, N0)\n  * Stage IIIA (N0-N2)\n  * Stage IIIB (T4, N0-2)\n  * Stage IIIC\n  * Inflammatory breast cancer\n* HER2/neu-positive disease by fluorescence in situ hybridization\n* Biopsy-accessible tumor\n* Measurable disease by physical examination or x-ray\n* No stage IV disease\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* At least 8 weeks\n\nHematopoietic\n\n* Absolute neutrophil count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n\nHepatic\n\n* Meets 1 of the following criteria:\n\n  * SGOT and SGPT \u2264 5 times upper limit of normal (ULN) AND alkaline phosphatase normal\n  * SGOT and SGPT \u2264 1.5 times ULN AND alkaline phosphatase \u2264 2.5 times ULN\n  * SGOT and SGPT normal AND alkaline phosphatase \u2264 5 times ULN\n* Bilirubin normal\n\nRenal\n\n* Creatinine normal\n* No pre-existing clinically significant renal disease that is not related to the malignancy\n\nCardiovascular\n\n* Ejection fraction \u2265 50% by MUGA\n* No pre-existing clinically significant cardiac disease that is not related to the malignancy\n* No history of congestive heart failure\n\nPulmonary\n\n* No pre-existing clinically significant pulmonary disease that is not related to the malignancy\n\nGastrointestinal\n\n* No severe malnutrition\n* No intractable emesis\n\nNeurologic\n\n* No pre-existing clinically significant neurologic disease that is not related to the malignancy\n* No peripheral neuropathy \u2265 grade 2\n\n  * No nerve damage from diabetes\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective non-hormonal contraception during and for 4 weeks after completion of study treatment\n* No known allergic reaction to study drugs\n* No active infection\n* No other malignancy except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* No other pre-existing clinically significant disease that is not related to the malignancy\n* No other serious or significant medical condition that would preclude study participation\n* No other contraindication to study treatment\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* No other concurrent immunotherapy\n\nChemotherapy\n\n* No prior chemotherapy for the malignancy\n* No other concurrent chemotherapy\n\nEndocrine therapy\n\n* No concurrent hormonal therapy for the malignancy\n\nRadiotherapy\n\n* No concurrent radiotherapy\n\nSurgery\n\n* No concurrent surgery for the malignancy\n\nOther\n\n* More than 2 weeks since prior and no concurrent herbal remedies or aspirin-containing products\n* No other concurrent investigational or commercial agents or therapies for the malignancy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}